Posters

Efficacy and tolerability of dorzolamide vs brinzolamide added to latanoprost/timolol combination as adjunctive anti-glaucoma therapy

Poster Details

First Author: Z.Kapsala GREECE

Co Author(s): D. Pagoulatos   C. Georgakopoulos                 

Abstract Details

Purpose:

To compare the efficacy and tolerability of dorzolamide versus brinzolamide as adjunctive anti-glaucoma treatment for patients with primary open-angle glaucoma (POAG) under latanoprost/timolol fixed combination.

Setting:

Ophthalmology Clinic, Ippokratio General Hospital of Athens, Athens, Greece.

Methods:

Patients with POAG under latanoprost/timolol fixed combination topical treatment were included in this prospective, randomized study. Intraocular pressure (IOP) should exceed the IOP-target necessitating the addition of further anti-glaucoma medication. One eye of each patient was selected for the analysis. There were two groups of eyes; in Group A dorzolamide eye drops were added, whereas in Group B brinzolamide eye drops were used. IOP was assessed before the addition of carbonic anhydrase inhibitor eye drops, at month 1 and month 3.

Results:

Thirty-eight patients were enrolled randomly in Group A (19 patients) and Group B (19 patients). Average IOP at month 1 and month 3 reduced to IOP target levels or lower for both study groups. Furthermore, no significant topical or systemic adverse events were documented for the studied treatments.

Conclusions:

It seems that both carbonic anhydrase inhibitor eye drops used in this study could be safely added in eyes with POAG under latanoprost/timolol fixed combination in case that further IOP reduction is needed. Additionally, IOP lowering effect was found to be similar for both therapeutic schemes.

Financial Disclosure:

None